表紙
市場調查報告書

肺動脈高血壓 (PAH):市場考察,流行病學及市場預測

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 535890
出版日期 內容資訊 英文 196 Pages
商品交期: 最快1-2個工作天內
價格
肺動脈高血壓 (PAH):市場考察,流行病學及市場預測 Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2030
出版日期: 2020年04月01日內容資訊: 英文 196 Pages
簡介

本報告提供肺動脈高血壓 (PAH)的疾病概要及主要7個市場 (美國,EU5個國家,與日本) 的流行病學提供著市場情況的相關分析,治療藥市場收益,被實施的治療方法,及流行病學的預測 (患病人數等) 。

第1章 主要考察

第2章 肺動脈高血壓 (PAH) 市場概要

第3章 疾病的背景和概要

  • 徵兆·症狀
  • 肺動脈高血壓 (PAH)的分類
  • PAH的功能分類
  • 流行病學
  • 風險要素
  • 病理學
  • 診斷
  • 治療

第4章 流行病學·患者人口

  • 要點
  • 人口·預測參數
  • 市場PAH的患病人數:主要7個國家

第8章 肺動脈高血壓 (PAH) 市場各國市場

  • 美國
    • PAH患病人數
    • PAH患病人數:各子類型
    • PAH患病人數:性別
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 治療流程

  • 目前治療方法
  • 治療指南
    • CHEST的指南 (美國)
  • European Society of Cardiology (ESC) 及 the European Respiratory Society (ERS)的指南

第7章 未滿足需求

第8章 上市藥

  • 認證·市場影響

第9章 上市藥:各企業

  • United Therapeutics Corporation
  • Actelion Pharmaceuticals Ltd.
  • GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
  • Bayer AG
  • Pfizer

第10章 上市藥的安全性·功效

第11章 新的治療方法

第12章 全球肺動脈高血壓 (PAH)的市場規模

  • 前提條件
  • 市場預測
  • 市場規模

第13章 主要7個市場分析

  • 主要調查結果
  • 肺動脈高血壓 (PAH)的主要7個市場的規模

第14章 各地區的市場規模

第15章 美國

第16章 歐洲5個國家

  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第17章 其他地區

第18章 其他歐洲

第19章 市場成長的促進要素

第20章 市場障礙

第21章 附錄

第22章 DelveInsight的服務內容

第23章 免責聲明

第24章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0017

DelveInsight's 'Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH's in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction.

The DelveInsight Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the PAH by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe and Japan.

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017. 

Pulmonary Arterial Hypertension Drug Chapters

This segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The therapeutic market of Pulmonary Arterial Hypertension is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the treatment of Pulmonary Arterial Hypertension. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of PAH. Letairis\Volibris (GlaxoSmithKline plc\Gilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the treatment of Pulmonary Arterial Hypertension. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodeling of blood vessels.

Pulmonary Arterial Hypertension Market Outlook

The Pulmonary Arterial Hypertension market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of PAH, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Pulmonary Arterial Hypertension Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pulmonary Arterial Hypertension Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Pulmonary Arterial Hypertension Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Pulmonary Arterial Hypertension Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Pulmonary Arterial Hypertension market
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension market
  • To understand the future market competition in the Pulmonary Arterial Hypertension market.

Table of Contents

1. Key Insights

2. Executive Summary of Pulmonary Arterial Hypertension

3. SWOT Analysis for Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017
  • 4.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030

5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH)

  • 5.1. Introduction
  • 5.2. Signs and Symptoms
  • 5.3. Classification of Pulmonary Arterial Hypertension (PAH)
    • 5.3.1. WHO classification
    • 5.3.2. Functional Classification of PAH
  • 5.4. Etiology
  • 5.5. Risk factors
  • 5.6. Pathophysiology
  • 5.7. Diagnosis
    • 5.7.1. Diagnostic Guidelines: European Guidelines of PAH

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. Population and Forecast Parameters
  • 6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH)

  • 7.1. The United States
    • 7.1.1. Total Prevalent Patient Population of PAH in the United States
    • 7.1.2. Sub-type Specific Prevalence of PAH in the United States
    • 7.1.3. Gender specific Prevalence of PAH in the United States
  • 7.2. Germany
    • 7.2.1. Total Prevalent Patient Population of PAH in Germany
    • 7.2.2. Sub-type Specific Prevalence of PAH in Germany
    • 7.2.3. Gender specific Prevalence of PAH in Germany
  • 7.3. France
    • 7.3.1. Total Prevalent Patient Population of PAH in France
    • 7.3.2. Sub-type Specific Prevalence of PAH in France
    • 7.3.3. Gender specific Prevalence of PAH in France
  • 7.4. Italy
    • 7.4.1. Total Prevalent Patient Population of PAH in Italy
    • 7.4.2. Sub-type Specific Prevalence of PAH in Italy
    • 7.4.3. Gender specific Prevalence of PAH in Italy
  • 7.5. Spain
    • 7.5.1. Total Prevalent Patient Population of PAH in Spain
    • 7.5.2. Sub-type Specific Prevalence of PAH in Spain
    • 7.5.3. Gender specific Prevalence of PAH in Spain
  • 7.6. The United Kingdom
    • 7.6.1. Total Prevalent Patient Population of PAH in the UK
    • 7.6.2. Sub-type Specific Prevalence of PAH in the UK
    • 7.6.3. Gender specific Prevalence of PAH in the United Kingdom
  • 7.7. Japan
    • 7.7.1. Total Prevalent Patient Population of PAH in Japan
    • 7.7.2. Sub-type Specific Prevalence of PAH in Japan
    • 7.7.3. Gender specific Prevalence of PAH in Japan

8. Treatment Algorithm

  • 8.1. Current Treatment Practices
  • 8.2. Treatment Guidelines
    • 8.2.1. CHEST Guidelines [The United States]
    • 8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

9. Unmet Needs

10. Case Studies

  • 10.1. A Rare Case of Drug Induced PAH
  • 10.2. A Case Report of Unconventional Delivery of Inhaled NO

11. Organizations related with PAH

12. Marketed Drugs

  • 12.1. Approval and Market Presence

13. Marketed Drugs by Companies

  • 13.1. United Therapeutics Corporation
  • 13.2. Johnson & Johnson
  • 13.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc.
  • 13.4. Bayer AG
  • 13.5. Pfizer

14. Safety and Efficacy of Marketed Drugs

15. Emerging Therapies

  • 15.1. Emerging Drugs Analysis
  • 15.2. Aurora-GT: United Therapeutics
    • 15.2.1. Other Developmental Activities
    • 15.2.2. Clinical Development
    • 15.2.3. Safety and Efficacy
  • 15.3. Ralinepag: United Therapeutics
    • 15.3.1. Other Developmental Activities
    • 15.3.2. Clinical Development
    • 15.3.3. Safety and Efficacy
  • 15.4. Liquidia Technologies
    • 15.4.1. Other Developmental Activities
    • 15.4.2. Clinical Development
    • 15.4.3. Safety and Efficacy
  • 15.5. Bardoxolone Methyl: Reata Pharmaceuticals
    • 15.5.1. Other Developmental Activities
    • 15.5.2. Clinical Development
    • 15.5.3. Safety and Efficacy
  • 15.6. Rodatristat Ethyl: Altavant Sciences
    • 15.6.1. Other Development Activities
    • 15.6.2. Clinical Development
    • 15.6.3. Safety and Efficacy
  • 15.7. Sotatercept: Acceleron Pharma
    • 15.7.1. Other Developmental Activities
    • 15.7.2. Clinical Development
    • 15.7.3. Safety and Efficacy
  • 15.8. PB1064: PhaseBio Pharmaceuticals
    • 15.8.1. Other Developmental Activities
    • 15.8.2. Clinical Development
    • 15.8.3. Safety and Efficacy
  • 15.9. CXA-10: Complexa
    • 15.9.1. Other Developmental Activities
    • 15.9.2. Clinical Development
    • 15.9.3. Safety and Efficacy

16. Other Promising Candidates

  • 16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies
    • 16.1.1. Other Developmental Activities
    • 16.1.2. Clinical Development
    • 16.1.3. Safety and Efficacy
  • 16.2. RT234: Respira Therapeutics
    • 16.2.1. Other Developmental Activities
    • 16.2.2. Clinical Development
    • 16.2.3. Safety and Efficacy

17. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis

  • 17.1. Key Findings
  • 17.2. Total Market Size of PAH in 7MM
  • 17.3. Market Outlook: 7MM

18. United States

  • 18.1. Total Market size of PAH
  • 18.2. PAH Market Size by Therapies

19. EU5 Countries

  • 19.1. Germany
    • 19.1.1. Total Market size of PAH
    • 19.1.2. PAH Market Size by Therapies
  • 19.2. France
    • 19.2.1. Total Market size of PAH
    • 19.2.2. PAH Market Size by Therapies
  • 19.3. Italy
    • 19.3.1. Total Market size of PAH
    • 19.3.2. PAH Market Size by Therapies
  • 19.4. Spain
    • 19.4.1. Total Market size of PAH
    • 19.4.2. PAH Market Size by Therapies
  • 19.5. United Kingdom
    • 19.5.1. Total Market size of PAH
    • 19.5.2. PAH Market Size by Therapies

20. Japan

  • 20.1. Total Market size of PAH
  • 20.2. PAH Market Size by Therapies

21. Market Drivers

22. Market Barriers

23. Appendix

  • 23.1. Bibliography
  • 23.2. Report Methodology

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables

  • Table 1: Summary of Pulmonary Arterial Hypertension (PAH) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Pulmonary Arterial Hypertension (PAH)
  • Table 3: Hemodynamic profiles of pulmonary hypertension
  • Table 4: Total Prevalent Patient Population of PAH in 7MM (2017-2030)
  • Table 5: Total Prevalent Population of PAH in the United States (2017-2030)
  • Table 6: Sub-type Specific Prevalence of PAH in the United States (2017-2030)
  • Table 7: Gender specific Prevalence of PAH in the United States (2017-2030)
  • Table 8: Total Prevalent Population of PAH in Germany (2017-2030)
  • Table 9: Sub-type Specific Prevalence of PAH in Germany (2017-2030)
  • Table 10: Gender specific Prevalence of PAH in Germany (2017-2030)
  • Table 11: Total Prevalent Population of PAH in France (2017-2030)
  • Table 12: Sub-type Specific Prevalence of PAH in France (2017-2030)
  • Table 13: Gender specific Prevalence of PAH in France (2017-2030)
  • Table 14: Total Prevalent Population of PAH in Italy (2017-2030)
  • Table 15: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
  • Table 16: Gender specific Prevalence of PAH in Italy (2017-2030)
  • Table 17: Total Prevalent Population of PAH in Spain (2017-2030)
  • Table 18: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
  • Table 19: Gender specific Prevalence of PAH in Spain (2017-2030)
  • Table 20: Total Prevalent Population of PAH in the UK (2017-2030)
  • Table 21: Sub-type Specific Prevalence of PAH in the UK (2017-2030)
  • Table 22: Gender specific Prevalence of PAH in the United Kingdom (2017-2030)
  • Table 23: Total Prevalent Population of PAH in Japan (2017-2030)
  • Table 24: Sub-type Specific Prevalence of PAH in Japan (2017-2030)
  • Table 25: Gender specific Prevalence of PAH in Japan (2017-2030)
  • Table 26: Recommendations for efficacy of drug monotherapy for PAH (group 1) according to WHO functional class.
  • Table 27: Recommendations for efficacy of initial drug combination therapy for PAH (group 1) according to WHO functional class
  • Table 28: Recommendations for efficacy of sequential drug combination therapy for PAH (group 1) according to WHO functional class
  • Table 29: Organizations contributing toward Pulmonary Arterial Hypertension
  • Table 30: Marketed Drugs for Pulmonary Arterial Hypertension - Approval and Market presence
  • Table 31: Marketed Drugs developed by United Therapeutics Corporation
  • Table 32: Marketed Drugs developed by Johnson & Johnson
  • Table 33: Marketed Drugs developed by GlaxoSmithKline Pharmaceuticals/ Gilead Sciences Inc.
  • Table 34: Marketed Drugs developed by Bayer (AG)
  • Table 35: Marketed Drugs developed by Pfizer
  • Table 36: Safety and Efficacy of Marketed Drugs
  • Table 37: Aurora-GT, Clinical Trial Description, 2020
  • Table 38: Ralinepag, Clinical Trial Description, 2020
  • Table 39: LIQ-861, Clinical Trial Description, 2020
  • Table 40: Bardoxolone Methyl, Clinical Trial Description, 2020
  • Table 41: Rodatristat Ethyl, Clinical Trial Description, 2020
  • Table 42: ACE-011, Clinical Trial Description, 2020
  • Table 43: PB1064, Clinical Trial Description, 2020
  • Table 44: PB1064, Clinical Trial Description, 2020
  • Table 45: iNO, Clinical Trial Description, 2020
  • Table 46: RT234, Clinical Trial Description, 2020
  • Table 47: 7 Major Market Size of PAH in USD Million (2017-2030)
  • Table 48: The US Market size of PAH in USD Million (2017-2030)
  • Table 49: The US market size of PAH by Therapies in USD Million (2017-2030)
  • Table 50: Germany Market size of PAH in USD Million (2017-2030)
  • Table 51: Germany market size of PAH by Therapies in USD Million (2017-2030)
  • Table 52: France Market size of PAH in USD Million (2017-2030)
  • Table 53: France market size of PAH by Therapies in USD Million (2017-2030)
  • Table 54: Italy Market size of PAH in USD Million (2017-2030)
  • Table 55: Italy market size of PAH by Therapies in USD Million (2017-2030)
  • Table 56: Spain Market size of PAH in USD Million (2017-2030)
  • Table 57: Spain market size of PAH by Therapies in USD Million (2017-2030)
  • Table 58: The UK Market size of PAH in USD Million (2017-2030)
  • Table 59: The UK market size of PAH by Therapies in USD Million (2017-2030)
  • Table 60: Japan Market size of PAH in USD Million (2017-2030)
  • Table 61: Japan market size of PAH by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Some of the common signs & symptoms of Pulmonary Arterial Hypertension (PAH)
  • Figure 3: Classification of Pulmonary Arterial Hypertension (PAH)
  • Figure 4: Functional Classification of PAH
  • Figure 5: Risk Factors of Pulmonary Arterial Hypertension
  • Figure 6: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
  • Figure 7: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
  • Figure 8: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
  • Figure 9: ESC/ERS Guidelines for the diagnosis of pulmonary hypertension
  • Figure 10: Total Prevalent Patient Population of PAH in 7MM (2017-2030)
  • Figure 11: Prevalence of PAH in the United States (2017-2030)
  • Figure 12: Sub-type Specific Prevalence of PAH in the United States (2017-2030)
  • Figure 13: Gender specific Prevalence of PAH in the United States (2017-2030)
  • Figure 14: Total Prevalent Population of PAH in Germany (2017-2030)
  • Figure 15: Sub-type Specific Prevalence of PAH in Germany (2017-2030)
  • Figure 16: Gender specific Prevalence of PAH in Germany (2017-2030)
  • Figure 17: Total Prevalent Population of PAH in France (2017-2030)
  • Figure 18: Sub-type Specific Prevalence of PAH in France (2017-2030)
  • Figure 19: Gender specific Prevalence of PAH in France (2017-2030)
  • Figure 20: Total Prevalent Population of PAH in Italy (2017-2030)
  • Figure 21: Sub-type Specific Prevalence of PAH in Italy (2017-2030)
  • Figure 22: Gender specific Prevalence of PAH in Italy (2017-2030)
  • Figure 23: Total Prevalent Population of PAH in Spain (2017-2030)
  • Figure 24: Sub-type Specific Prevalence of PAH in Spain (2017-2030)
  • Figure 25: Gender specific Prevalence of PAH in Spain (2017-2030)
  • Figure 26: Total Prevalent Population of PAH in the UK (2017-2030)
  • Figure 27: Sub-type Specific Prevalence of PAH in the UK (2017-2030)
  • Figure 28: Gender specific Prevalence of PAH in the United Kingdom (2017-2030)
  • Figure 29: Total Prevalent Population of PAH in Japan (2017-2030)
  • Figure 30: Sub-type Specific Prevalence of PAH in Japan (2017-2030)
  • Figure 31: Gender specific Prevalence of PAH in Japan (2017-2030)
  • Figure 32: Treatment Options for Pulmonary Arterial Hypertension (PAH)
  • Figure 33: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)
  • Figure 34: Unmet Needs of PAH
  • Figure 35: 7 Major Market Size of PAH in USD Million (2017-2030)
  • Figure 36: Market Size of PAH in the United States, USD Millions (2017-2030)
  • Figure 37: The U.S. market size of PAH by therapies in USD Million (2017-2030)
  • Figure 38: Market Size of PAH in Germany, USD Millions (2017-2030)
  • Figure 39: Germany market size of PAH by therapies in USD Million (2017-2030)
  • Figure 40: Market Size of PAH in France, USD Millions (2017-2030)
  • Figure 41: France market size of PAH by therapies in USD Million (2017-2030)
  • Figure 42: Market Size of PAH in Italy, USD Millions (2017-2030)
  • Figure 43: Italy market size of PAH by therapies in USD Million (2017-2030)
  • Figure 44: Market Size of PAH in Spain, USD Millions (2017-2030)
  • Figure 45: Spain market size of PAH by therapies in USD Million (2017-2030)
  • Figure 46: Market Size of PAH in the UK, USD Millions (2017-2030)
  • Figure 47: The UK market size of PAH by therapies in USD Million (2017-2030)
  • Figure 48: Market Size of PAH in Japan, USD Millions (2017-2030)
  • Figure 49: Japan market size of PAH by therapies in USD Million (2017-2030)
  • Figure 50: Market Drivers
  • Figure 51: Market Barriers